Patents by Inventor Harold Chapman
Harold Chapman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210009551Abstract: Provided herein, inter alia, are methods and compounds for treating a pulmonary disease, fibrosis, or cancer.Type: ApplicationFiled: June 2, 2017Publication date: January 14, 2021Inventors: Harold A. Chapman, Ying WEI, Bradley J. BACKES
-
Patent number: 7427591Abstract: Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide based inhibitors of cathepsin S are also described.Type: GrantFiled: August 5, 2004Date of Patent: September 23, 2008Assignees: Massachusetts Institute of Technology, Brigham and Women's HospitalInventors: Hidde L. Ploegh, Harold A. Chapman, Richard J. Riese, Paula R. Bryant, Matthew S. Bogyo
-
Patent number: 7285525Abstract: Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide-based inhibitors of cathepsin S are also described.Type: GrantFiled: April 19, 2002Date of Patent: October 23, 2007Assignees: Massachusetts Institute of Technology, Brigham & Women's Hospital Inc.Inventors: Hidde L. Ploegh, Harold A. Chapman, Richard J. Riese, Paula R. Bryant, Matthew S. Bogyo
-
Patent number: 7094752Abstract: Novel peptides that are capable of binding to uPAR and inhibiting the binding of an integrin and vitronectin are described. Also provided are nucleic acid sequences encoding the novel peptides. Methods for screening for small molecules, other peptides, or peptoids that mimic the antagonistic function of the peptides of the invention are described. The invention has applications in design of therapeutics for treating disorders characterized by upregulation of uPA and uPAR, and cancer and chronic inflammation, cell migration or uPAR: integrin binding interactions, and diagnostical applications to such disorders.Type: GrantFiled: April 9, 2004Date of Patent: August 22, 2006Assignees: Chiron Corporation, Brigham and Women's Hospital Harvard Medical SchoolInventors: Steven Rosenberg, Michael V. Doyle, Harold A. Chapman
-
Publication number: 20050095248Abstract: Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide based inhibitors of cathepsin S are also described.Type: ApplicationFiled: August 5, 2004Publication date: May 5, 2005Applicants: Massachusetts Institute of Technology, Brigham and Women's HospitalInventors: Hidde Ploegh, Harold Chapman, Richard Riese, Paula Bryant, Matthew Bogyo
-
Publication number: 20050080010Abstract: Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide based inhibitors of cathepsin S are also described.Type: ApplicationFiled: August 14, 2003Publication date: April 14, 2005Inventors: Hidde Ploegh, Harold Chapman, Richard Riese, Paula Bryant, Matthew Bogyo
-
Publication number: 20040265797Abstract: Novel peptides that are capable of binding to uPAR and inhibiting the binding of an integrin and vitronectin are described. Also provided are nucleic acid sequences encoding the novel peptides. Methods for screening for small molecules, other peptides, or peptoids that mimic the antagonistic function of the peptides of the invention are described. The invention has applications in design of therapeutics for treating disorders characterized by upregulation of uPA and uPAR, and cancer and chronic inflammation, cell migration or uPAR: integrin binding interactions, and diagnostical applications to such disorders.Type: ApplicationFiled: April 9, 2004Publication date: December 30, 2004Applicant: Chiron CorporationInventors: Steven Rosenberg, Michael V. Doyle, Harold A. Chapman
-
Patent number: 6794358Abstract: Novel peptides that are capable of binding to uPAR and inhibiting the binding of an integrin and vitronectin are described. Also provided are nucleic acid sequences encoding the novel peptides. Methods for screening for small molecules, other peptides, or peptoids that mimic the antagonistic function of the peptides of the invention are described. The invention has applications in design of therapeutics for treating disorders characterized by upregulation of uPA and uPAR, and cancer and chronic inflammation, cell migration or uPAR: integrin binding interactions, and diagnostical applications to such disorders.Type: GrantFiled: September 23, 1998Date of Patent: September 21, 2004Assignee: Brigham and Women's HospitalInventors: Steven Rosenberg, Michael V. Doyle, Harold A. Chapman
-
Patent number: 6773704Abstract: The invention provides methods of treating and preventing vascular diseases, by inhibiting cysteine proteases active at sites of vascular injury, particularly cathepsins K and S, by administering cystatin C or TGF-&bgr;1. Cystatin C is severely reduced in both atherosclerotic and aneurysmal aortic lesions. Also provided is a method of diagnosing a patient at risk of, or with, vascular injury by detecting low levels of circulating cystatin C.Type: GrantFiled: October 26, 2000Date of Patent: August 10, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Harold A. Chapman, Guo-Ping Shi, Peter Libby, Galina K. Sukhova, Daniel I. Simon
-
Publication number: 20030166534Abstract: Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide-based inhibitors of cathepsin S are also described.Type: ApplicationFiled: April 19, 2002Publication date: September 4, 2003Applicant: Massachusetts Institute of TechnologyInventors: Hidde L. Ploegh, Harold A. Chapman, Richard J. Riese, Paula R. Bryant, Matthew S. Bogyo
-
Patent number: 6608030Abstract: Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of Class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide-based inhibitors of cathepsin S are also described.Type: GrantFiled: May 19, 1999Date of Patent: August 19, 2003Assignee: Brigham & Women's Hospital, Inc.Inventors: Hidde L. Ploegh, Harold A. Chapman, Richard J. Riese, Paula R. Bryant, Matthew S. Bogyo
-
Patent number: 5830850Abstract: The present invention relates to methods and compositions for the amelioration of symptoms caused by bone resorption disorders, including but not limited to osteoporosis, arthritides and periodontal disease, and damage caused by macrophage-mediated inflammatory processes. In one embodiment, the methods and compositions of the invention include methods and compositions for the specific inhibition of cathepsin K activity. In an additional embodiment, the methods and compositions of the invention include methods and compositions for the specific inhibition of cathepsin K activity coupled with specific inhibition of at least a second activity involved in the bone resorption and/or macrophage-mediated inflammatory processes. In a particular embodiment, the methods and compositions of the invention include methods and compositions for the specific inhibition of cathepsin K and cathepsin S activity.Type: GrantFiled: August 28, 1996Date of Patent: November 3, 1998Assignees: Mount Sinai School of Medicine of the City of New York, Brigham and Women's HospitalInventors: Bruce D. Gelb, Harold Chapman, Robert J. Desnick
-
Patent number: D775942Type: GrantFiled: October 14, 2015Date of Patent: January 10, 2017Assignee: Global Products International Group, LLCInventors: Gabriel Paul Chapman, Ryan Harold Chapman
-
Patent number: D780556Type: GrantFiled: October 12, 2015Date of Patent: March 7, 2017Assignee: Global Products International Group, LLCInventors: Gabriel Paul Chapman, Ryan Harold Chapman
-
Patent number: D843821Type: GrantFiled: October 12, 2015Date of Patent: March 26, 2019Assignee: Global Products International Group, LLCInventors: Gabriel Paul Chapman, Ryan Harold Chapman